Navigation Links
Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
Date:5/21/2009

Both Phase III pivotal trials begin enrollment in May 2009; Reinforces Lilly's commitment to Alzheimer's disease and biotech product research

INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease. The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2,000 patients age 55 and over from 16 countries.

In 2008, Lilly began enrolling patients in two Phase III clinical trials called IDENTITY and IDENTITY 2 for a different potential treatment for Alzheimer's disease, a gamma-secretase inhibitor that also affects amyloid beta, which is believed to be one of the underlying pathologies of the disease. Patients or caregivers interested in learning how to enroll in either EXPEDITION trial or the IDENTITY trials should visit www.clinicaltrials.gov or call 1-877-CTLilly (1-877-285-4559). In combination, the EXPEDITION and IDENTITY trials will include approximately 4,600 patients with Alzheimer's disease in over 30 countries around the world.

EXPEDITION and EXPEDITION 2 -
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
2. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
3. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
4. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
5. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
8. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
9. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
10. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
11. Lilly and TransPharma Medical Announce Licensing and Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
... , Jan. 28 , Net Sales of $1.11 ... period (an increase of 2.5% constant currency) , Diluted ... from the prior year period, and $1.12 adjusted, an increase of 12.0% ... of $4.10 billion for the full year represent a decrease of 0.6% ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Zimmer Reports Fourth Quarter and 2009 Financial Results 2Zimmer Reports Fourth Quarter and 2009 Financial Results 3Zimmer Reports Fourth Quarter and 2009 Financial Results 4Zimmer Reports Fourth Quarter and 2009 Financial Results 5Zimmer Reports Fourth Quarter and 2009 Financial Results 6Zimmer Reports Fourth Quarter and 2009 Financial Results 7Zimmer Reports Fourth Quarter and 2009 Financial Results 8Zimmer Reports Fourth Quarter and 2009 Financial Results 9Zimmer Reports Fourth Quarter and 2009 Financial Results 10Zimmer Reports Fourth Quarter and 2009 Financial Results 11Zimmer Reports Fourth Quarter and 2009 Financial Results 12Zimmer Reports Fourth Quarter and 2009 Financial Results 13Zimmer Reports Fourth Quarter and 2009 Financial Results 14Zimmer Reports Fourth Quarter and 2009 Financial Results 15Zimmer Reports Fourth Quarter and 2009 Financial Results 16Zimmer Reports Fourth Quarter and 2009 Financial Results 17Zimmer Reports Fourth Quarter and 2009 Financial Results 18Zimmer Reports Fourth Quarter and 2009 Financial Results 19Zimmer Reports Fourth Quarter and 2009 Financial Results 20Zimmer Reports Fourth Quarter and 2009 Financial Results 21Zimmer Reports Fourth Quarter and 2009 Financial Results 22Zimmer Reports Fourth Quarter and 2009 Financial Results 23Zimmer Reports Fourth Quarter and 2009 Financial Results 24Zimmer Reports Fourth Quarter and 2009 Financial Results 25Zimmer Reports Fourth Quarter and 2009 Financial Results 26Zimmer Reports Fourth Quarter and 2009 Financial Results 27
(Date:7/13/2014)... According to a new market research report "Heterogeneous ... GPU, DSP, connectivity), Technology Node (45nm-5nm), Application (Consumer, ... and Analysis to 2014-2020", published by MarketsandMarkets, the ... expected to reach $61.70 Billion by 2020, growing ... 2020. , Browse 71 market data Tables with ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... as a surprise to politicians and rights leaders alike, mainly ... of girls in the 0-6 years category is coming down ... feticide and nothing else. The problem is that we are ... the guilty," said Health Minister P.K. Sreemathy Thursday while speaking ...
... Southwestern Medical Center, working with mice, have shown how ... decrease the fearful response associated with reliving a traumatic ... a mild electrical shock – mice in the study ... place where it happened, a condition that could be ...
... found a breakthrough in the treatment of breast cancer ... therapies.// ,According to Professor Miles Prince from Melbourne's ... emission tomography (PET) would probably change the way breast ... (PET) scans to monitor breast cancer patients to find ...
... in UK, 40% Of Adults Cannot Manage Without Cell ... Stoke-on-Trent, who had conducted the research//, claimed that certain ... their cell phones. In his study on how students ... of the behaviors displayed, closely resembled symptoms of ‘pathological ...
... Richards marks the rapid increase in esophageal cancer cases in the ... cancer.// Only 16 % or around 2,200, of the 14,000-esophageal cancer ... years. ,There has been a 6-fold annual rise in the ... to experts. Rise in obesity cases has been the major cause. ...
... can be effective in cluster headaches as well, researchers ... pain signals, Dr. Peter Goadsby, professor of clinical neurology ... not as common as migraines and affect one in ... In the final analysis 69 patients were included. These ...
Cached Medicine News:Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 2Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 3Health News:Aussie Doctors Claim Breakthrough in Breast Cancer Treatment 2Health News:Rise in Esophageal Cancer is emphasized by Richards’ deat 2
Microsect Curette with increased cutting edge and modified shaft, 10"....
Bone Curette, 160 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: